31 December 2003

To crush or not to crush - buprenorphine tablet administration

Drug and Alcohol Review (2003) 22;4:471-2


Muhleisen P, Spence J, Nielsen S. Crushing buprenorphine tablets.



In Australia, as in most of the research reports, buprenorphine is generally given under supervision of the nurse or pharmacist. As with methadone, there is more supervision for new and unstable patients with take-away dosing permitted to some degree for stable patients after periods in treatment. For example in South Australia up to 5 days may be dispensed in a week with 2 supervised doses after 18 months in stable treatment. In NSW up to two doses may be given per week for those needing daily doses under certain conditions, and for emergencies, travel, etc. Reports from France show that a proportion of doses there are also given under supervision although this is not by regulation but just �good practice�. The issue of whether tablets should be given whole, bisected or crushed is debated.

A report in this month's Drug and Alcohol Review covers this area from a practical perspective from a team which has been using the drug for over 5 years (originally running a trial). This group in Melbourne initially crushed tablets for some patients who they suspected were diverting the drug. Others requested crushed tablets to reduce administration time. Then the Victorian Health authorities, who are not known for their liberal attitudes, nor strong evidence base, advised all buprenorphine to be 'substantially broken or crushed'. Too fine crushing, however, is reported by these authors to sometimes result in a 'powder' which may be swallowed and thus remain largely unabsorbed. Thus crushing can cause problems in the attempt to avoid them.

These authors quote reports of about a quarter of buprenorphine patients attempting to inject their drug on at least one occasion but only less than 5% continuing to do so when they could. This is probably not too different from rates of injecting of methadone syrup.

"Merely crushing doses does not stop diversion or injecting..." <snip>

"Adequate supervision is still the basis of good treatment in this field, and is not replaced by dose-crushing. All professionals involved in the treatment should be diligent in their responsibilities in ensuring that the treatment is safe and effective. Clients who continue to misuse their buprenorphine could be considered unsuitable for treatment with this more expensive and time-consuming drug and an option to minimize potential harm to the client and the treatment itself is to suggest transfer to dosing with methadone, which is still the gold standard opioid substitution treatment."

My personal feeling is that the drug was approved by the TGA in the current tablet forms and most patients should receive the doses in that form. The tablets should only be crushed for good clinical reasons, and then only with the consent and understanding of the patients involved. Otherwise it could be seen as another paternalistic manoeuvre perpetuating the 'them and us' attitude so prevalent in drug clinics around the world.

comments by Andrew Byrne ..

12 December 2003

60 year follow-up of Boston drinkers.

Vaillant GE. A 60-year follow-up of alcoholic men. Addiction 2003 98:1043-1051

Dear Colleagues,

In a staggering feat, veteran alcohol researcher George Vaillant has followed the classic Boston study groups of Glueck & Glueck for up to 60 years from enrolment. These two groups included over 700 citizens either from poor inner city areas or from Harvard University undergraduates, most born in the 1920s. There are significant findings on the natural histories of alcohol abuse, dependence, abstinence and controlled drinking in relation to other medical problems, employment, self-help and mortality. Most importantly there is information on the onset of alcohol problems since the subjects were chosen young and at random. There is some bias since alcoholics are less likely to comply with such research but the differences in responses were not significant in this case.

There is more in this paper than could be included in a brief review. However, the main finding given by Vaillant in his abstract is that despite major differences in the groups in terms of IQ, social background and ethnicity, the main outcomes were very similar in four important domains by age 70. As also found by Drew, chronic alcohol dependence was rare in the older age groups. Controlled drinking was exceptional (1%). Just over half the subjects had died in both groups and around 10% were abusing alcohol (but not dependent) with most of the remainder abstinent.

‘Surprisingly, in both samples, alcohol abuse could persist for decades without remission, death or progression to dependency.’ [of 29 college alcohol abusers 13 surviv(ed) to age 80]. But there were some differences between the groups: ‘The average age of onset of alcohol abuse was a decade later for the college men (40 vs. 30) than it was for the core city men.’

I felt very proud when I completed a ten year follow-up of opiate dependent patients a few years ago. But my achievement is dwarfed by this monumental piece of work in the case of alcohol since Vaillant has now carefully examined outcomes over more than an average adult lifetime of three score years and ten.

comments by Andrew Byrne ..

Oral lofexidine versus naloxone injections for detox. American Journal of Addiction.

The Effectiveness of Combined Naloxone/Lofexidine in Opiate Detoxification: Results from a Double-blind Randomized and Placebo-controlled Trial. Beswick T, Best D, Bearn J, Gossop M, Rees S, Strang J. American Journal of Addiction 2003 12;4:295-305

Dear Colleagues,

This intriguing trial from a London based group gave frequent injections of naloxone to addicts in a detoxification ward.

The authors state that methadone ‘has been the standard treatment for in-patient opioid detoxification’. This may be the case in England but not necessarily elsewhere. There seems to be an assumption that lofexidine (and/or clonidine) are safe and effective in outcomes of opioid withdrawal episodes. Although there are apparently fewer hypotensive side effects with lofexidine (‘Brit-Lofex), a recent study from England, a generation of experience and the absence of a reported black market would seem to cast some doubt on their efficacy in successful heroin withdrawals. Next comes the rather controversial and little-researched use of naloxone in drug withdrawal. These researchers gave most subjects over 30 hypodermic injections, a behaviour which most of us are actively trying to discourage.

After finding that there were no significant differences in overall outcomes in those randomised to receive the antagonist naloxone, the authors come to the surprising conclusion that more research is needed on this treatment modality for those trying to quit heroin. With the increasing use of buprenorphine for detoxification, it would seem almost outlandish to support the use of injectable, short acting antagonists like naloxone.

About half of the 33 references are from the authors themselves which may indicate their pre-eminence in the field of opioid detoxification.

Comments by Andrew Byrne ..

Article on inheritance of addiction in Iran. One in 15 offspring opioid-dependent.

Ahmadi J, Arabi H, Mansouri Y. Prevalence of substance abuse among offspring of opioid addicts. Addictive Behaviors (2003) 28:591-595

Dear Colleagues,

This fascinating study from Iran tells us some basic facts about drug use and inheritance in that population. With major differences with western experience in drug and alcohol use there, the significance for our own populations is somewhat limited.

The authors interviewed 500 randomly chosen adult offspring of 2000 addicts in treatment in Shiraz, Iran. Evidently the average age of those in treatment is much higher than our patients since 28% of their offspring were over 40 years of age and 80% married (but still living under the one roof, a condition of the survey).

The authors remind us of the ‘old tradition of drug use’ in Persia, including opium which is used for pleasure as well as as a medicine. While all these drugs are currently illegal, and penalties severe, drug use and dependency are still common. Even alcohol, which is ‘both religiously and legally prohibited’ has significant reported use and dependency. In the first degree relatives of opioid addicts there was substantial ‘ever used’, ‘current use’ and ‘dependency’. There was no reported use of cocaine or psychodelics. Stimulants were not mentioned.

In short, the findings were that among the offspring of opioid addicts in Iran, 20% had ‘ever used’ opium or heroin and 6.4% were currently opiate dependent. Tobacco was ‘ever used’ by 36% with 24% being currently dependent by DSM-IV criteria. In 95% of the opioid used was opium and 5% heroin. Males greatly outnumbered females for most forms of drug use by up to 9:1. The survey was evenly split, however.

Alcohol was ‘ever used’ by 18.2% and cannabis products by only 4.2%. Thus over half of the population had used a psychoactive drug (56.4%) excluding caffeine.

These researchers asked the respondents the reason for their drug use. ‘Enjoyment’ was the prime answer (57%). Next came ‘modeling’ (50%) [which I take to be something akin to ‘peer pressure’] and then ‘release of tension’ (34%).

In our own patient population in Redfern we have a median age of 37 years. On cursory exmination, we could identify only twelve patients out of 328 from the past three years who had adult children and only two of these had a known drug dependency history. Hence, while this paper shows distinct differences between drug use in different countries, drug use can certainly run in families as with other habits, partially as a result of genetics and partly environmentally induced (see elegant twin studies from Minneapolis St Paul).

Comments by Andrew Byrne ..

Australian national opioid treatment guideline publications August 2003.

Commonwealth Department of Health and Aging. Australian national treatment guidelines (full citations and internet address below) published Aug 03

Dear Colleagues,

Below are the web contacts for the Australian National treatment guidelines which were distributed in December 2003 by the Department of Health and Aged Care in Canberra. There are four volumes, a full and abbreviated version for both methadone and naltrexone. The authors are to be congratulated on a 'generic' set of instructions for the basic approaches to maintenance treatments, regardless of where this may be given.

http://www.healthyactive.gov.au/internet/main/publishing.nsf/Content/phd-illicit-methadone-treatment (old 1997 version)

http://www.health.gov.au/internet/main/publishing.nsf/Content/phd-illicit-methadone-cguide-s (abbreviated version 2003)

http://www.health.gov.au/internet/drugstrategy/publishing.nsf/Content/pharmacotherapy
(link to other guidelines available for buprenorphine, naltrexone, methadone, etc)

Australia’s eight different jurisdictions have eight different sets of treatment rules, from quite liberal (South Australia) to almost barbaric (Northern Territory). However, doctors do not normally have the liberty of giving sub-standard treatment because of the jurisdiction they practice in. According to the British Medical Journal, where there is clear research evidence, doctors are normally required to follow it. Hence, as these Guidelines point out, all Australian opioid dependent residents should have access to appropriate dose levels of the right drug in the right setting. Also, in all community treatment settings there should be some level of take-away dosing available for stable patients as this improves compliance and retention rates, according to these Guidelines. In the absence of regular take-away doses one of the most important ‘incentives’ of supervised methadone treatment is lost and patients may feel condemned to almost daily attendance indefinitely (as apparently sometimes happens in Victoria as well as the NSW public sector clinics). If local rules should impinge on appropriate dosing, they should be addressed and overcome in the interests of making treatment safe, effective and humane (for example the ACT rules on daily methadone doses of over 100mg; the Victorian DOH will allow waivers for take-home doses under certain circumstances if doctors apply appropriately).

An area of major difficulty in these and other guidelines remains induction protocol for methadone. Mortality from overdose in the first week has caused a knee-jerk reduction in starting doses from 40mg to 20mg in some settings. However, there has been no evaluation of this rather dramatic change and it may well have caused an increase in treatment drop-outs. Despite the stated wide variations in methadone metabolism in these guidelines, no clinical protocol is given for determining who is a fast metaboliser and thus may need higher doses. In one paper it is stated that due to variable absorption and metabolism of methadone, “the rate of clearance from the body has been reported to vary by a factor of almost 100” [Ward J, Bell J, Mattick RP, Hall W. Methadone Maintenance Therapy for Opioid Dependence. A guide to appropriate use. (1996) CNS Drugs. 6;6:440-449]. Thus increasing doses by only 10mg per week may take many months to reach optimal levels in some folk who may need 200mg or even more to achieve ‘normal’ or therapeutic blood levels.

There is no substitute for careful clinical assessment and gradual dose adjustments for this drug, as with insulin, digoxin or Dilantin in unstable folk at the commencement of treatment. Perhaps somebody should describe a ‘sliding scale’ for methadone inductions. The American Health Department “TIP” protocols allow up to 60mg on the first day in three divided doses under very close clinical supervision. Few clinics can support the clinical supervision necessary for this, hence 40mg is the usual starting dose in many cases in the USA. Most Australian drug services now apparently use a standard 30mg starting dose in the great majority of cases.

I hope this is of assistance for colleagues involved in methadone and buprenorphine treatments. Naltrexone should only be prescribed for opioid dependency in specialist settings, whereas for alcoholism all primary care physicians should be familiar with it.

Andrew Byrne ..

Clinical guidelines and procedures for the use of methadone in the maintenance treatment of opioid dependence - Abbreviated version (pdf file 176Kb) Date Published: 2003 ISBN: 0 642 82263 8
Author: National Drug Strategy Australian Government Department of Health and Ageing.

19 November 2003

APSAD annual scientific meeting. Brisbane Nov 17-19 2003. Day 3

Australian Professional Society on Alcohol and other Drugs (APSAD)



On the third and final conference day Professor Ian Webster spoke eloquently about how we may need to change our thinking on drug and alcohol matters to look at a wider picture. He gave many examples from history, pointing out that by the time antibiotics for TB and other infections were invented, the incidence of bacterial diseases was already very much in decline. Thus he emphasised the multifactorial nature of causations for change and that nothing could work unless it had community support. The Australian experience with random breath testing, first starting in Tasmania, caused immediate and significant reductions in road deaths. Several terms were new to me this week, one being �communitarian�.

The second speaker was renowned Kiwi researcher David Fergusson whose studies include a rigorous longitudinal follow-up of over 1000 individuals born in Christchurch in 1974. Their exposure to, problematic use or and/or dependency on cannabis is just one of many facets which have been closely examined every year or so for over 25 years.

Professor Fergusson said that being involved in cannabis epidemiology, he was obliged to deal with drug law reformers but did not see himself as an advocate. He stated that most researchers have some pre-conceived ideas, such as �cannabis is safe� or �cannabis is extremely dangerous� (neither of which is probably true). Thus they often end up proving their own ideas without necessarily contributing much to science. He used the example of Vegemite which could become the subject of a health study. One might find common harmful associations while others might show no significant difference between those who eat Vegemite and normal controls who (naturally) shun the product. This example is telling as for nutritional reasons Vegemite had its salt content changed at one time to reduce its potential public health impact.

The rest of this third day was given over to numerous papers in concurrent sessions covering a variety of dependency subjects, including Aboriginal Health, prevention strategies, brief interventions, psychostimulant treatments (much speculation here, apparently ), Drug Courts and Diversion from the judicial system. Afternoon parallel sessions mostly continued from the morning but also included parenting, pregnancy and more alcohol subjects.

The final session included some very important items including release of the new General Practice smoking cessation guidelines by Robyn Richmond, self help report from We Help Ourselves (WHO) by Garth Popple and other discussion about dissemination of evidence into practice. I think that Professor Saunders was the only medical doctor in this final line-up of eight. Despite supplying most of the public health dependency interventions in Australia, GPs and pharmacists were not well represented this year. Perhaps the next APSAD conference in Perth, WA in November 2004 will redress this issue.

Comments by Andrew Byrne ..

18 November 2003

APSAD annual scientific meeting. Brisbane Nov 17-19 2003. Day 2

Australian Professional Society on Alcohol and other Drugs (APSAD)



Dear Colleagues,

This action-packed second conference day had a couple of light points which punctuated an otherwise serious scientific program on dependency management, policy, etc.

Three keynote plenary speakers were led by George Koob talking on how basic sciences can inform treatment decisions. He had written an amusingly-titled paper �Cocaine Reward and Dopamine Receptors: Love at First Site� which was parallel to much of his talk. But there seems to be a complete �disconnect� between such coherent scientific efforts to understand addiction and the almost complete absence of logic in American drug treatment policy over the years. The next speaker, Professor Rudolf Moos, also from California, seemed to be equally hampered in his talk on �how treatment should inform and influence research�. As regards opiates, only a small proportion of the total US dependent population receive appropriate treatment, thus skewing findings, outcomes and policies when compared with other western countries where most people have access to treatment. It was still a privilege indeed to hear the seven invited, diverse and eminent American speakers during the conference (Ling, Vocci, Davis, Maxwell, Grabowski were the others).

The last plenary speaker was Margaret Hamilton giving her ideas on getting research into practice. She gave a �mea culpa� (or her customized plural �we-are culpa�) concerning deficiencies of her own institution. She conceded that sometimes important findings were still not promulgated before researchers �went on to write the next paper�. This is not unique to her institution, of course, nor to our field. However, it is a reminder that we all need to look at our current practices and see if they are consistent with established guidelines as well as new innovations as defined by the evidence. This applies to drug prescribing as well as other components or �black box� factors which are always harder to define than drug, dose and manner of administration.

One of the light points was an afternoon debate on the premise �Are we drowning in the gene pool?� Wittily introduced by Ross Young, two opposing teams of 3 took turns to make light of the subject, starting with Alison Ritter. She had done some homework on drosophila fruit flies put through a silo-like �enebriometer�, courtesy of some ancient vivisecting biologist. George Koob gave a brief but pointed speech including sex, drug and rock/roll, thus taking the genetic low moral ground, but gaining at the same time total audience sympathies. Professor Moos also gave an amusing and increasingly contradictory description of the subject for the affirmative. After the use of an early Picasso absinthe drinker the day before, Dr Barbara Mason ended the presentations (following John Whitfield from RPAH and Nick Martin) with a Degas reproduction, including male emigr� looking the worse for the popular fin-de-siecle drink.

Modern technology now allows a unique level of audience participation using remote multi-choice equipment. On the Monday, a panel discussion on clinical alcohol presentations used the device to gain audience responses to numerous questions (there were 10 seconds of agonising �musak� after which beautiful color-coded histograms appeared for each of the several options). Gerry Springer uses a similar technique on some of his seedier shows, I believe. Even some unlikely options were chosen by participants, eg: response to intoxicated patient: �telephone 000 and hit him with a ruler�!. It was somewhere between a jury room and a flesh market as case histories were gradually revealed and the various possible treatment interventions canvassed by first the audience and then the panels in turn. The alcohol cases on Monday were followed on the Tuesday with an opiate using pregnant woman and a violent stimulant abuse case. The panels included Ingrid van Beek, Alan Gijsbers, Richard Mattick, Roger Brough and many more. For some reason these interesting sessions were not well attended yet other sessions on opioid therapies, pain management, club drugs, rapid detox, neurobiology, genetics etc were nearly all full to overflowing during the conference. It was a shame that there were not more middle sized rooms in the hotel complex, but it is always difficult to predict such matters ahead of time.

A second session on neurobiology included Professor Mac Christie speaking on neuroadaptation followed by papers on club and party drugs and the users� personality traits, genetic polymorphism etc from a Hong Kong study by Alfreda Stadlin. Frank Vocci took the prize for complexications with his final paper on GABA-B receptors and their possible effects in cocaine withdrawals (something others say does not exist). His statements about the occasional incomprehensibility of his papers was appreciated by the audience. The issue of using dexamphetamine or other stimulants for cocaine users was raised by several speakers during the conference.

There was an illuminating session on the 1999 NSW Drug Summit and its longer term consequences given by Dr Tony Gill, John Leary and Larry Pierce, chaired by James Bell. We were reminded that short term political expedience can sometimes give rise to longer term benefits. Substantially more funding was put into public methadone services; case management was made mandatory and clinic accreditation and a take-away dose review commenced. After a comment about the public clinics� withdrawal of all take-home doses due to alleged problems with diversion, John Grabowski made some pertinent comments from the audience. He said that research in the US showed that most diverted methadone was in fact used by other addicts who were not currently registered, thus making �another layer of unofficial treatment�. Professor Grabowski also quoted research showing that take-away dosing improves retention rates and overall outcomes of methadone treatment in his own country, the USA. Despite being generally considered more conservative than Australia, US authorities now allow a week or even more consecutive �home� dosing in certain long term, stable cases. A user representative at the meeting stated that she found the attention paid to consumer views at the NSW Drug Summit were generally not followed up with actions, including the �Treatment Agreement� and other matters. She said it was �lip service only� for some of the �too difficult� issues. It was also said that despite leading many changes in drug treatments, that the NSW Health Department had done very little in evaluating these policy changes for their benefits and costs.

The chair reminded us that the most novel outcome of the Summit was the Kings Cross injecting room which has indeed been extensively evaluated - with almost universally positive outcomes officially reported. It was recently granted a 4 year extension and now attracts up to 350 injectors daily.

There were also parallel sessions on prevention, dual diagnosis, workforce development, NGO�s, tobacco, diversion/policing, etc. All were well received and choice was very difficult on some occasions.

The �Rankin Oration� was given in the presence of Jim Rankin by Margaret Hamilton who donned yet another hat to give an impression of what the future might bring. No clairvoyant, she nevertheless made many far-sighted predictions about �virtual conferences�, tropical island existence, brain �chips� and intimate interactive telecommunications. She confessed to not understanding all the neurobiology but said she was starting to make some inroads after all the lectures on the limbic system, transmitter chemicals and the like.

Incredibly, not content with launching two publications the previous day, she also announced yet another book, this time from Turning Point in collaboration with Trevor King who was also present and took a bow. I look forward to seeing how the Victorians approach this field and how it needs to be improved.

There was a private meeting of the newly formed Chapter of Addiction Medicine (RACP) of which there are almost 150 members across all states and territories. The APSAD annual general meeting was held on the Monday evening with a psychiatry college sub-group meeting also held at the conference.

The conference dinner was held in the Sheraton ballroom which was almost unrecognisable from an hour earlier as the stage was set for pseudo-Phantom of the Opera and para-Pavarotti and Bialla Boheme, each bringing joy and sonorous shrills to the air. We even had the world cup theme sung as a trio! [Nessun dorma for those who know Turandot, the opera]

Dr James Bell gave a witty address showing how the need for a Chapter of Addiction Medicine was itself a kind of dependency, complete with craving, salience and divers other attributes. He raised a few laughs with his comparison of the Foundation Fellowship Committee with Phillip Ruddock (any babies overboard here?), and a reference to certain doctors keeping their patients on high doses of drugs in order to minimise the time they spend with them, maintain their dependency and �to ensure the viability of their practices�. Serious allegations, even in the bacchanalian context.

The wine flowed, the dance floor filled and several dour professors became agile dancers and ardent romantics. Some others ended up under the table, in one case literally. A credit to the organising committee in Brisbane.

Comments by Andrew Byrne ..

17 November 2003

APSAD annual scientific meeting. Brisbane Nov 17-19 2003. Day 1

Monday 17th Nov 2003



Australian Professional Society on Alcohol and other Drugs (APSAD)



Dear Colleagues,

The first day of the APSAD conference incorporated a very full program from 9am until 10pm. Welcome formalities were performed by Professor John Saunders, Aboriginal Elder Auntie Roz Graham and Minister Trish Worth with a letter of support to all delegates from the Prime Minister. Mats Berglund from Sweden then spoke about �what government can expect from treatment�, followed by a historical perspective from Neal Blewett regarding the Australian response to drugs and viral diseases over the past 20 years. He gave a hilarious description of his own need to back-track after seemingly supporting decriminalisation of cannabis as a federal minister in the 1980s.

A new magazine called �Of Substance� was then launched by Brian Watters and Margaret Hamilton. This quarterly is hoped to fill a �niche� in the dependency market. Its first two copies will be free, then it will cost $50 per year.

A bewildering array of concurrent sessions were then held in six separate rooms. First were post detoxification vocational services in cities. Next were �free papers� on opiate dependence treatment, starting with a description by Deborah Zador of a rather negative opinion survey of 104 English patients on injectable methadone and heroin. Those on methadone expressed a preference for heroin and many found prescribed doses inadequate. Malcolm Dobbin described the explosion in prescribing of benzodiazepines, long acting morphine and other drugs and their negative impacts. Nico Clark told us about some buprenorphine patients who required morphine and other drugs for serious surgical pain. One such was given up to 300mg morphine daily but sent home, still sick and immobile, with a prescription for daily methadone 40mg from a chemist they could not get to. Such a patient should have had adequate analgesic doses dispensed, regardless of existing �regulations� which should be waived when they stand in the way of good treatment. If the patient were not considered safe with such medicines then the GP and/or district nurse should have been called in to assist with supervision. Nick Lintzeris then reminded us of how little research literature there is on the interaction between benzodiazepines and opiates. He quoted the few animal studies which supported the notion of additive effects, consistent with the French experience of buprenorphine overdose deaths of which 80% were associated with benzodiazepines, alcohol being involved in most of the rest. A series of 50 rapid detox cases were then presented by a Sydney group, half the cases receiving a naltrexone implant with the remainder oral prescription. Nine of the 24 oral cases had relapsed in a six month period compared with only one of the implant group.

Carolyn Edmonds and Jason White performed a wonderful service by carefully examining the effect of a single dose of naltrexone on binge drinking footballers, double blind, cross-over in about 10 subjects. They found no overall effect on quantity of alcohol consumed but some effects of the perception of the drink itself. This session included numerous other short papers on alcohol. Jane Maxwell started the session on party drugs, explaining that research in this area was particularly messy, as well exemplified by the �Science� paper on MDMA which had to be withdrawn by its authors after erroneous conclusions due to the wrong reagent being used in lab experiments. She reminded us of the very local nature of some drug habits and differences which can occur even between adjacent areas. This was taken up by John Grabowski, also from Texas, in his afternoon plenary speech on the use of dexamphetamine in cocaine users. There was also a session on �pathways to treatment� and the �consumer perspective�.

The afternoon started with 6 parallel sessions followed by a wonderful description of the �science of opiate treatment� by Wim van den Brink from Holland. His own heroin trial for treatment resistant addicts was described in detail (smoked/injected; up to a gram per day; good outcomes in treatment; bad outcomes returned with end of trial) as well as his support for higher doses in methadone treatment. This was echoed by John Grabowski who described several approaches to psychostimulant use in the USA. Next we had the launch of yet another publication �Dealing with Risk�, also by Margaret Hamilton and Brian Watters. I wonder if it is a record for the same pair to launch two publications at opposite ends of the same (very long) day? Copies were handed out to all delegates the following morning (perhaps as a reward for making it to the second day!).

The evening brought welcome drinks and nibbles, followed by three international speakers on pharmacotherapies for alcoholism. It was nice to see our interstate and overseas colleagues again but a shame that so much about alcohol research was repeated while the wine flowed freely and perhaps we should have been relaxing.

comments by Andrew Byrne ..

11 November 2003

New England Journal trial supports office based buprenorphine treatment with generous take-home provisions.

Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins K. Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D. Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone. NEJM (2003) 349:949-958

Dear Colleagues,

This study randomised consenting heroin dependent subjects to receive one month’s treatment with (i) buprenorphine, (ii) buprenorphine/naloxone or (iii) placebo. For a further 11 months, surviving (sic) patients were followed in an open-label manner for primary outcome measure of 'percentage of urine drug screens negative for opiates' as well as for safety.

The double blind treatment was given for one month, supervised for weekdays with take-home doses for weekends. Doses were fixed at 16mg buprenorphine, 4mg naloxone. In the open label study there were more liberties with up to 10 consecutive doses being dispensed for home consumption.

The authors seem to have been surprised that results (retention and drug screens) for the placebo group quickly became more than 3 standard deviations away from those in the active treatment groups. Under their agreed protocol this triggered abandonment of the placebo arm of the trial, but not before a substantial excess of treatment drop outs and relapses to illicit drugs.

The paper leaves many questions unanswered. What was the 12 month retention rate? Significant numbers of late drop-outs must have occurred as there is a shortage of urine drug screens reported from the open label study. We are not told whether the patients with abnormalities to liver function tests thought to be ‘possibly’ or ‘probably’ related to the treatment (7 cases) were prescribed pure buprenorphine or the combination product.

These subjects were presumably told that they had a one in three chance of being given no active drug and would thus may have had to face opiate detoxification.

The ethics of researchers offering placebos for serious conditions has been dealt with in detail since this paper’s genesis in 1996. These authors may be reluctant to be associated with such a practice today.

This trial is only of very limited relevance since it did not compare office based practice with standard US clinic treatment. Nor were the conditions the same as current licence arrangements in the US (no supervised doses are required!). In essence, the trial patients on bup/naloxone combination showed slightly more side effects (?significance) but comparable reductions in illicit drug use .. and similar early retention rates compared with those taking the pure sublingual tablet without the naloxone. Hence the combination drug conferred no particular advantage for the patient and, being a mixed drug, may have some disadvantages over the pure drug. Thus there would seem to be no proof that the combination drug is either better for the patient, nor that it is necessarily better for the public health situation in America. This lack of good scientific evidence favouring the use of the combination product provides yet another challenge for American doctors. It is to be hoped that this trial will, however, give strong support for allowing more unsupervised buprenorphine doses in Australian settings where such dispensed doses are still the exception. For 8 years in France most doses of the pure drug buprenorphine have been unsupervised and most indications are positive.

Comments by Andrew Byrne ..

Some opiate antagonist therapy 'escaped the usual process of therapeutic controls'.

Streel E, Verbanck P. Ultra-rapid opiate detoxification: from clinical application to basic science. Addiction Biology (2003) 8:141-146

Dear Colleagues,

This ‘Invited Review’ from Brussels describes the rise of opiate antagonist therapy over the past 20 years, much of which has ‘escaped the usual process of therapeutic controls’. We are told that most new treatments should start with animal studies - yet with antagonists the reverse has happened. These two Belgian authors quote some of their own recent work on addicted rats given anaesthetics and antagonists to quell the symptoms and signs of opiate withdrawal. Objective findings are hard enough to find (ever tried to detect pin-point pupils in a rat?) - but subjective withdrawal effects are necessarily even more elusive (where is the Pied Piper when you need him?). The authors quote a number of studies showing contradictory effects on withdrawals from anaesthetics, sedatives and antagonists. Some even concluded that animal modelling, at least with rats, was not applicable for rapid opiate detoxification (‘ROD‘).

The article contains two major misconceptions, starting with the first line that rapid detoxification ‘has become increasingly popular in both private and public addiction centres’ (no reference). The treatment has never been ‘popular’ in public treatment agencies I am aware of, nor is its use necessarily still increasing in the for-profit sector. Secondly, the authors seem to have been persuaded that naltrexone maintenance therapy leads to long-term abstinence in a substantial proportion of those who are prescribed it. The evidence I have read is otherwise, with reported compliance as low as 10% at 6 to 12 months. Promising outcomes were reported in only three of the many well conducted trials - and two of these three utilised enforced supervision in the prison or probation system (Chan 1996; Cornish 1997). The encouraging outcomes of Gerra (1995) were never replicated by other researchers. Excess deaths and self harm were reported in one trial (Miotto 1997). Australian studies have been equally disappointing (Foy 1998) although mortality was not specifically sought from official sources so final outcomes remain uncertain for those who were lost to the authors’ follow up.

Like certain other authors on the subject, Streel and Verbanck state that the process is probably best conceptualised as ‘rapid antagonist induction’ and not ‘rapid detoxification’. This almost sounds like a ‘mantra’ from some. In fact, the process is both of these, and the problem is not conceptualisation, but whether the overall treatment is actually both ‘safe and effective’ for addicted patients who receive it.

It is to the credit of Addiction Biology that, like Lancet, it is prepared to publish items at the ‘edge’ of medical practice, some of which would be rejected by more ‘purist‘ journals. Rapid detoxification under anaesthetic/sedation and naltrexone implants are still not evidence-based modalities and some of these reports may not fit all aspects of the ‘Farmington consensus’ introduced by NAC sister journal, Addiction.

The list of 43 references in this invited review is a who’s who of the field, including Loimer, Brewer, Resnick, Kleber, Strang, Seoane, Legarda, Currie, O’Neil and Hulse. The article emphasises the need to do animal studies and ‘basic science’ prior to introducing treatments into clinical practice. The authors thus regret the situation where the use of naltrexone implants and long acting depot preparations are not always first used in appropriate laboratory experiments. The article makes persuasive reading.

Comments by Andrew Byrne ..